scholarly journals The rate of smallpox vaccine-associated adverse events in the United States, and smallpox preparedness activities by the Netherlands, Germany, and WHO

2003 ◽  
Vol 7 (9) ◽  
Author(s):  
Keyword(s):  
United States ◽  
Adverse Events ◽  
Signs And Symptoms ◽  
The United States ◽  
Smallpox Vaccine ◽  
Smallpox Vaccination ◽  
Serious Adverse Events ◽  
Control And Prevention ◽  
Life Threatening ◽  
Ongoing Surveillance

The Centers for Disease Control and Prevention (CDC) and state health departments in the United States are conducting ongoing surveillance for adverse effects due to smallpox vaccine during the civilian smallpox vaccination programme (1). Out of 4213 civilian healthcare workers vaccinated between 24 January and 14 February 2003, no potentially life threatening or moderate to severe adverse events have been reported. Seven vaccine recipients were reported to have non-serious adverse events. The most common signs and symptoms were fever (n=two), rash (n=two), malaise (n=two), pruritis (n=two), hypertension (n=two), and pharyngitis (n=two) (Table).

Safety and Clinical Outcomes of an Equine-derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States

2019 ◽  
Vol 70 (9) ◽  
pp. 1950-1957 ◽  
Author(s):  
Jason S Richardson ◽  
Geraldine S Parrera ◽  
Hugo Astacio ◽  
Harpreet Sahota ◽  
Deborah M Anderson ◽  
...  
Keyword(s):  
United States ◽  
Mechanical Ventilation ◽  
Adverse Events ◽  
Clinical Outcomes ◽  
Kidney Injury ◽  
Final Diagnosis ◽  
The United States ◽  
Serious Adverse Events ◽  
Underlying Illness ◽  
Life Threatening

Abstract Background Botulism is a rare, life-threatening paralytic illness. Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine) (BAT) manufactured by Emergent BioSolutions Canada Inc is an equine-derived heptavalent botulinum antitoxin product indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A-G in adults and pediatric patients. BAT product was US-licensed in 2013. Methods In the United States, from October 2014 through July 2017, safety and clinical outcomes data were collected under a registry for patients treated with BAT product. Results Registry patients had a median age of 51 years (range, 32 days to 92 years). Among 162 patients, 7 (4.3%) experienced BAT product–related serious adverse events, including 1 (0.6%) report each of pneumonia, pneumonia aspiration, ventricular tachycardia, upper gastrointestinal hemorrhage, anaphylactic reaction, acute kidney injury, and acute myocardial infarction. Thirty-one (19.1%) patients had 41 BAT product–related adverse events. Six (3.7%) deaths were reported in the registry. All deaths were attributed to the underlying illness and were assessed as unlikely related to BAT product. Among 113 (69.8%) patients with a final diagnosis of botulism, those treated early (≤2 days) spent fewer days in the hospital (5 vs 15.5 days), in the intensive care unit (ICU) (4 vs 12 days), and on mechanical ventilation (6 vs 14.5 days) than those treated late (>2 days), respectively. Conclusions BAT product was well tolerated in patients. Treatment with BAT product at ≤2 days of symptom onset was associated with shorter hospital and ICU stays, and shorter duration and need for mechanical ventilation, showing clinical benefit associated with early treatment.

Serious Adverse Events Reported with Dietary Supplement Use in the United States: A 2.5 Year Experience

2018 ◽  
Vol 17 (2) ◽  
pp. 227-248 ◽  
Author(s):  
Stephen M. Schmitz ◽  
Hector L. Lopez ◽  
Douglas Mackay ◽  
Haiuyen Nguyen ◽  
Paula E. Miller
Keyword(s):  
United States ◽  
Adverse Events ◽  
Dietary Supplement ◽  
The United States ◽  
Serious Adverse Events ◽  
Supplement Use ◽  
Dietary Supplement Use

An Overview of Acute Flaccid Myelitis

2021 ◽  
Vol 20 ◽  
Author(s):  
Aseem Setia ◽  
Jasween Bhatia ◽  
Sankha Bhattacharya
Keyword(s):  
United States ◽  
Signs And Symptoms ◽  
The United States ◽  
Sudden Onset ◽  
Clinical Findings ◽  
The Body ◽  
Difficult Situation ◽  
Acute Flaccid Myelitis ◽  
Control And Prevention ◽  
Diagnostic Approaches

: Acute Flaccid Myelitis is defined by the presence of Acute Flaccid Paralysis (AFP) and a spinal cord lesion on magnetic resonance imaging that is primarily limited to the grey matter. AFM is a difficult situation to deal with when you have a neurologic illness. According to the Centers for Disease Control and Prevention (CDC), a large number of cases were discovered in the United States in 2014, with 90% of cases occurring in children. Although the exact cause of AFM is unknown, mounting evidence suggests a link between AFM and enterovirus D68 (EV-D68). In 2014, an outbreak of AFM was discovered in the United States. The condition was initially linked to polioviruses; however, it was later found that the viruses were caused by non-polioviruses Enteroviruses D-68 (EV-D68). The number of cases has increased since 2014, and the disease has been declared pandemic in the United States. The sudden onset of muscle weakness, usually in an arm or leg, as well as pain throughout the body, the patient's facial expression changing to one of weakness, and shortness of breath, ingesting, and speaking are all common symptoms in patients suffering from neurologic disease. This article includes graphic and histograms representations of reported AFM incidents and criteria for causality, epidemiology, various diagnostic approaches, signs and symptoms, and various investigational guidelines. It also includes key statements about recent AFM disease clinical findings.

Sign in / Sign up

Export Citation Format

Share Document